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Abstract
Background: Beta-catenin, a component of the Wingless/Wnt signaling pathway, can activate target genes linking
with the adenomatous polyposis coli (APC) gene in colorectal cancer. The purpose of this study is to investigate
whether nuclear beta-catenin overexpression in metastatic sentinel lymph node(s) [SLN(s)] is associated with
synchronous liver metastasis.
Methods: Clinicopathological data from 355 patients (93 cases with liver metastasis and 262 cases without liver
metastasis) were reviewed. Beta-catenin expression in metastatic SLN(s) and liver metastatic lesions was examined
by immunohistochemistry. The association of nuclear beta-catenin expression in metastatic SLN(s) and liver
metastatic lesions was evaluated, and the relationship between nuclear beta-catenin expression and
clinicopathological characteristics was analyzed. Finally, univariate and logistic multivariate regression analyses were
adopted to discriminate the risk factors of liver metastasis.
Results: Nuclear beta-catenin overexpression in metastatic SLN(s) was observed in 70 patients with liver metastasis
and 31 patients without liver metastasis (75.3% vs. 11.8%; P < 0.001). Nuclear beta-catenin expression was noted in
all the metastatic lesions. Spearman rank correlation analysis demonstrated that nuclear beta-catenin expression in
metastatic SLN(s) had a positive correlation with that in metastatic lesions (r = 0.425, P < 0.001). Univariate and
multivariate analyses indicated that nuclear beta-catenin overexpression in metastatic SLN(s) correlated with liver
metastasis.
Conclusions: Nuclear beta-catenin overexpression in metastatic SLN(s) is strongly associated with liver metastasis
and may contribute to predict liver metastasis.
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Background
Colorectal cancer (CRC) is one of the most common
cancers and the second leading cause of cancer-related
deaths in the western world, which usually result from
uncontrolled metastatic disease. The most common
organ metastasis in CRC patients is the liver. For
patients with local CRC, the five-year survival rate
approaches 90%; however, in metastatic patients, this
rate decreases to 19% [1]. The rate of liver metastasis in
clinical CRC patients is 5.5%-33.3% [2]. Thus, early
detection of liver metastasis in CRC is especially impor-
tant to improve patient survival rate. Several studies
have investigated the risk factors influencing liver metas-
tasis [3-7]. Histopathologically, the presence of venous
invasion [8,9], a deeper level of invasion, less differen-
tiated carcinoma cells and the presence of lymph node
metastasis have been reported to be risk factors [10].
The biological factors related to liver metastasis have
been identified as EGF [6], Arp2 [5], TGF-a [11], CD44
[12], and CD10 [13,14].
It has been suggested that CRC might show cellular
dedifferentiation in the invasive area, with loss of an
epithelial phenotype and a gain of a mesenchymal phe-
notype, which facilitates invasive and metastatic growth
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any medium, provided the original work is properly cited.of originally differentiated cancer cells. The malignant
progression is called an epithelial-mesenchymal transi-
tion (EMT) [15-17]. One of the key oncogenic proteins
that might drive EMT in colorectal carcinogenesis is
beta-catenin [18]. Its localization relates to its function
in cancer growth [19]. Beta-catenin in cytoplasm and
membrane binds with the intracellular domain of E-cad-
herin, which is a cell-to-cell adhesion molecule, and
then plays a significant role in maintaining normal tissue
architecture. Nuclear beta-catenin associates with mem-
bers of the TCF/LEF family of transcription factors [20]
and acts as a transcriptional activator of numerous tar-
get genes, exerting predominantly tumor-promoting
functions. Increased nuclear beta-catenin has been
shown to correlate with liver metastasis in CRC [21].
The impact of sentinel lymph node biopsy (SLNB) has
been profound in the treatment of melanoma [22,23] and
breast carcinoma [24,25]. Over the past decade, numer-
ous studies have investigated this technology in other dis-
eases including gastrointestinal carcinoma [26]. SLNB in
CRC is investigational and the potential impact of this
technique on the overall treatment of this disease could
be significant [27]. In CRC, the lymphatic drainage pro-
ceeds from the submucosal lymphoid follicles through
the bowel wall to the epicolic, paracolic, and finally, the
para-aortic nodes [28]. The SLN(s) are the first to receive
l y m p h a t i cd r a i n a g ef r o mt h ep r i m a r yt u m o r .T h e ya l s o
have the greatest chance of harboring metastasis when
the disease has metastasized to the regional lymphatic
basin. Focused pathologic examination of SLN(s) has
been used to efficiently search for metastatic disease that
may not be identified by standard histopathologic meth-
ods. Previous studies demonstrated that SLN mapping
and immunohistochemical diagnosis of SLN micrometas-
tases can improve staging accuracy in CRC, and intrao-
perative diagnosis of SLN micrometastases is crucial for
planning the operation and the determination of adjuvant
therapy [29]. A recent report indicated that increased
expression of hnRNP A1, Ezrin, tubulin beta-2C, and
Annexin A1 in metastatic SLN(s) suggests a significantly
elevated early CRC metastasis [30].
Although the association of nuclear beta-catenin
expression in CRC with liver metastasis has been
reported, the previous study focused mainly on beta-
catenin expression in primary tumors. Correlation
between nuclear beta-catenin expression in metastatic
SLN(s) and matched liver metastatic lesions is unknown.
Herein, the nuclear beta-catenin expression in meta-
static SLN(s) and matched liver metastatic lesions was
investigated to identify the relationship between both
expressions. Meanwhile, the relationship between
nuclear beta-catenin expression and clinicopathological
characteristics was analyzed. Finally, univariate and
logistic multivariate regression analyses were adopted to
discriminate the risk factors of liver metastasis. In this
study, nuclear beta-catenin overexpression in SLN(s)
was shown to be associated with synchronous liver
metastasis. This study is the first to elucidate this rela-
tionship based on clinical and pathological data. The
clinical significance of this research is that the provision
of a promising predictor of liver metastasis in CRC.
Methods
Study population and data collection
This study cohort comprised 355 CRC patients with
metastatic SLN(s) who underwent treatment in the Pro-
vincial Hospital and the Qianfoshan Hospital affiliated
to Shandong University from March 2001 to March
2009. There were 247 men and 108 women. Their mean
age was 65 years, ranging from 35 to 85 years. Of the
355 cases, 93 had synchronous liver metastasis. Tumor
stage was based on the American Joint Committee on
Cancer TNM staging system (6th edition, 2002) [31].
The inclusion criteria were as follows: (1) patients
underwent surgical treatment and were histologically
identified as having CRC and liver metastasis; (2) liver
metastasis was identified within six months after finding
the primary tumor; and (3) patients with no prior his-
tory of liver-directed treatment and radiofrequency abla-
tion. The exclusion criteria were as follows: (1) liver
metastasis arose after surgical treatment; (2) patients
accepted other treatment simultaneously, such as che-
motherapy; (3) hereditary non-polyposis colorectal can-
cer patients and patients with familial adenomatous
polyposis; (4) patients with other liver diseases, such as
liver cirrhosis; and (5) patients with extrahepatic metas-
tasis. All 355 patients fulfilled the inclusion criteria. On
the other hand, 23 cases whose liver metastasis arose
after surgical treatment, 11 cases who accepted che-
motherapy, 1 case of familial adenomatous polyposis, 2
cases with liver cirrhosis and 5 cases with extrahepatic
metastases were excluded. This study was approved by
Ethics Committee of Provincial Hospital and Qianfoshan
Hospital. Clinical information related to diagnostic pro-
cedures and clinicopathological characteristics were col-
lected from medical records.
Ex vivo sentinel node mapping technique
Ex vivo sentinel node mapping was performed as
described previously [32]. Briefly, within 10 min of
resection, colorectal specimens were divided along their
anti-mesenteric border with a scalpel, thereby exposing
the tumor with approximately 4 cm of normal mucosa
proximally and distally. Next, 1-1.5 mL Lymphazurin
(Isosulfan blue dye; Tyco, OH) was injected with a
tuberculin syringe quadrantically around the tumor.
This was performed subserosally if the tumor was above
the peritoneal reflection, or submucosally if below it,
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reflection. Injection areas were gently massaged for 2-3
min to generate the flow of dye along the lymphatics.
The first 1-4 lymph nodes stained blue were designated
SLN(s). The SLN specimen was then placed directly
into formalin. Two designated pathologists performed
routine pathologic evaluation 24-72 hours later.
Immunohistochemistry
The specimens from patients were embedded in paraffin
and cut into sections for immunohistochemical staining.
Informed consent for the use of the specimens was
obtained from all patients. Immunohistochemical stain-
ing was performed with the streptavidin peroxidase
complex method. Tissue sections of 4 μMt h i c k n e s s
were deparaffinized and microwaved for 15 min, twice
in 10 mM citrate buffer (pH 6.0) at 100°C to retrieve
the antigens, followed by incubation in 3% H2O2 for 10
min to quench the endogenous peroxidase. Nonspecific
binding of antibodies was inhibited by incubation in 5%
normal goat serum for 20 min in a humid chamber. Tis-
sue sections were then incubated with mouse monoclo-
nal anti-beta-catenin antibody (diluted 1:50, mouse
IgG1; Cell Signaling Technology, Boston, USA) over-
n i g h ta t4 ° C .A f t e rt h r e ew a s h e sw i t hP B S ,t i s s u es e c -
tions were incubated with biotinylated goat anti-mouse
IgG for 30 min at room temperature. After washing,
slides were incubated in streptavidin-peroxidase com-
plex for 20 min at 37°C, washed three times, visualized
using DAB, and counterstained with hematoxylin. As a
negative control, sections were stained without the addi-
tion of a primary antibody.
As for the immunohistochemistry assessment, six
sights were selected randomly and observed at × 400
magnification by two pathologists. The immunostained
slides were scored as described previously [33]. Briefly,
the immunostained slides were scored using the sum of
signal intensity (0 = no expression; 1 = weak expression;
2 = moderate expression; 3 = strong expression) and the
percentage of positive cells (% tumor cells: 0 = 0%; 1 =
1%-25%; 2 = 26%-50%; 3 = 51%-75%; and 4 = 76%-
100%). If a moderate or strong expression was observed
in the nuclei, then nuclear beta-catenin immunoreactiv-
ity in SLN(s) was regarded as positive. Nuclear beta-
catenin overexpression was defined as a positive nuclear
beta-catenin expression in > 50% of tumor cells. This
cutoff value was chosen after a preliminary quantifica-
tion because it was close to the mean value.
Statistical analysis
Statistical analysis was carried out using SPSS 16.0.
Spearman rank correlation analysis was used to evaluate
the relationship of nuclear beta-catenin expression in
metastatic SLN(s) and liver metastatic lesions. The c2
and Fisher exact tests were adopted to analyze the cor-
relation between nuclear beta-catenin expression and
clinicopathological characteristics. Finally, univariate and
logistic multivariate regression analyses were adopted to
discriminate the independent risk factors of liver metas-
tasis. P < 0.05 was considered statistically significant.
Results
Nuclear beta-catenin expression in SLN(s) and liver
metastatic lesions
A total of 777 metastatic lymph nodes from 355
patients were excised and processed. The mean number
in each patient was 2.4 ± 1.3. Beta-catenin expression
was observed in all the SLN specimens. Nuclear beta-
catenin expression was observed in metastatic SLN(s) in
101 patients. In patients without liver metastasis beta-
catenin presented mostly in a membrane-associated
staining pattern (Figure 1B). Nuclear beta-catenin over-
expression in metastatic SLN(s) was observed in 31
c a s e s( 1 1 . 8 % ) .I np a t i e n t sw i t h liver metastasis, nuclear
beta-catenin overexpression in metastatic SLN(s) could
be observed in 70 cases (75.3%) (Figure 1C). Nuclear
beta-catenin overexpression in metastatic SLN(s) was
more evident in patients with liver metastasis than in
patients without liver metastasis (P < 0.001). On the
other hand, nuclear beta-catenin expression was noted
in all the metastatic lesions (Figure 1D). Spearman rank
correlation analysis indicated that nuclear beta-catenin
expression in metastatic SLN(s) had a positive correla-
tion with that in metastatic lesions (r = 0.425, P <
0.001) (Table 1).
Relationship between nuclear beta-catenin expression in
SLN(s) and clinicopathological characteristics
The c2 test was performed to investigate the relation-
ship between nuclear beta-catenin expression in meta-
static SLN(s) and clinicopathological features. Beta-
catenin expression in metastatic SLN(s) was significantly
different for age (P < 0.001), type of tumor (P < 0.001),
tumor cell differentiation (P < 0.001), tumor invasion
depth (P < 0.001), lymph node metastasis (P = 0.003),
liver metastasis (P < 0.001) and TNM stage (P < 0.001)
(Table 2).
Nnuclear beta-catenin overexpression in SLN(s) is an
independent risk factor of synchronous liver metastasis
To discriminate independent the risk factors of synchro-
nous liver metastasis, clinicopathological characteristics
were divided into two groups according to liver metasta-
sis. Univariate analysis and logistic multivariate regres-
sion model were adopted to discriminate the risk factors
of liver metastasis. The c2t e s td e m o n s t r a t e dt h a tl i v e r
metastasis is associated with age (P < 0.001), tumor size
(P = 0.001), type of tumor (P = 0.002), tumor cell
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0.002), lymph node metastasis (P = 0.001) and nuclear
beta-catenin overexpression in metastatic SLN(s) (P <
0.001) (Table 3). However, logistic multivariate regres-
sion analysis retained only six factors in the model
(Table 4). These factors are age (P = 0.004), tumor size
(P = 0.002), tumor invasion depth (P < 0.001), tumor
cell differentiation (P = 0.023), lymph node metastasis
(P = 0.002) and nuclear beta-catenin overexpression in
metastatic SLN(s) (P < 0.001).
Discussion
To investigate whether nuclear beta-catenin overexpres-
sion in metastatic SLN(s) is correlated with synchronous
liver metastasis, beta-catenin expression in metastatic
SLN(s) and matched liver metastatic lesions in 355 CRC
Figure 1 Beta-catenin expression in metastatic SLN(s) and liver metastatic lesions (×400). (A) Normal SLN (B) beta-catenin presents mostly
in a membrane-associated staining pattern in metastatic SLN(s) in patients without liver metastasis (C) Nuclear beta-catenin is overexpressed in
metastatic SLN(s) in patients with liver metastasis (D) Nuclear beta-catenin expression in liver metastatic lesions.
Table 1 Correlation between nuclear beta-catenin expression in SLN(s) and the matched liver metastatic lesions
beta-catenin expression
in SLN(s)
beta-catenin expression in liver metastatic lesions Total
1-25% 26-50% 51-75% 76-100%
1-25% 0 2 0 0 2
26-50% 0 9 11 1 21
51-75% 0 0 37 8 45
76-100% 0 0 20 5 25
Total 0 11 68 14 93
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data were analyzed retrospectively. Nuclear beta-catenin
overexpression in SLN(s) has been demonstrated to be
associated with synchronous liver metastasis. According
to our knowledge, this study is the first to elucidate the
relationship between nuclear beta-catenin overexpres-
sion in SLN(s) and synchronous liver metastasis using
clinical and pathological data. The clinical significance
of the current study is the provision of a promising pre-
dictor of liver metastasis in CRC.
Beta-catenin is a key component of adherens junc-
tions, which are necessary for homophilic cell-cell adhe-
sions [34]. Membranous beta-catenin determines the
epithelial phenotype; nuclear beta-catenin represents a
Table 2 Correlation of nuclear beta-catenin expression in




n ≤ 50% > 50%
Gender
Male 247 178 69 0.745
Female 108 76 32
Age
≤ 55 54 15 39 < 0.001
> 55 301 239 62
Tumour localization
Rectum 203 145 58 0.954
Colon 152 109 43
Tumour size (cm)
≤ 5 120 90 30 0.303
≤ 5 235 164 71
Type of tumour
Adenocarcinoma 299 221 78 < 0.001
Mucinous adenocarcinoma 31 11 20
Signet-ring cell carcinoma 16 14 2
Undifferentiated carcinoma 9 8 1
Tumour cell differentiation
Well/moderately differentiated 279 218 61 < 0.001
Poorly differentiated 76 36 40
Tumour invasion depth
T1 5 5 0 < 0.001
T2 63 56 7
T3 252 176 76
T4 35 17 18
Lymph node metastasis
< 4 123 100 23 0.003
≥ 4 232 154 78
Liver metastasis
Negative 262 231 31 < 0.001
Positive 93 23 70
TNM stage
I 5 5 0 < 0.001
II 20 20 0
III 237 206 31
IV 93 23 70
* P value is the result of c
2 test in the same factor, and < 0.05 is considered
statistically significant.
Table 3 Clinicopathological risk factors classified
according to liver metastasis
Risk factors Liver Metastasis P*
n Negative Positive
Gender
Male 247 182 65 0.939
Female 108 80 28
Age
≤ 55 54 22 32 < 0.001
> 55 301 240 61
Tumour localization
Rectum 203 150 53 0.965
Colon 152 112 40
Tumour size (cm)
≤ 5 120 102 18 0.001
> 5 235 160 75
Type of tumour
Adenocarcinoma 299 232 67 0.002
Mucinous adenocarcinoma 31 17 14
Signet-ring cell carcinoma 16 9 7
Undifferentiated carcinoma 9 4 5
Tumour cell differentiation
Well/moderately differentiated 279 236 43 < 0.001
Poorly differentiated 76 26 50
Tumour invasion depth
T1 5 5 0 0.002
T2 63 20 1
T3 252 221 72
T4 35 25 20
Lymph node metastasis
< 4 123 104 19 0.001
≥ 4 232 158 74
Nuclear beta-catenin expression in SLN(s)
≤ 50% 254 231 23 < 0.001
> 50% 101 31 70
* P value is the result of c
2 test in the same factor, and < 0.05 is considered
statistically significant.
Table 4 Variables in the equation for the multivariate
logistic regression model
Risk factors B S.E Wald Df Sig. Exp
(B)
Nuclear beta-catenin in SLN(s) 1.787 0.316 23.744 1 < 0.001 9.118
Tumour invasion depth 1.635 0.365 15.533 1 < 0.001 7.213
Tumour size 1.372 0.413 8.435 1 0.002 5.317
Lymph node metastasis 1.368 0.482 8.173 1 0.002 4.759
Age 1.317 0.471 7.456 1 0.004 3.337
Tumour cell differentiation 1.214 0.544 4.739 1 0.023 2.458
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Wnt signaling pathway [35]. A recent study indicated
that the expression of E-cadherin-catenin complex in
SLN in breast carcinoma is related to tumor morphol-
ogy [36]. In the current study, only those with synchro-
nous liver metastasis were included to exclude the
influence of treatments such as operative procedures
and chemotherapy. Our data demonstrated that nuclear
beta-catenin overexpression in metastatic SLN(s) is
more evident in patients with liver metastasis than in
patients without liver metastasis. This finding suggests
that nuclear beta-catenin overexpression in metastatic
SLN(s) correlates with synchronous liver metastasis. In
addition, a nuclear beta-catenin expression was observed
in the matched liver metastatic lesions, which had a
positive correlation with nuclear beta-catenin expression
in the metastatic SLN(s). All the above-mentioned
immunohistochemical data indicated that the accumula-
tion of nuclear beta-catenin in metastatic SLN(s) may
correlate with the formation of liver metastatic lesion in
CRC.
With regard to correlation between nuclear beta-cate-
nin in metastatic SLN(s) and clinicopathological charac-
teristics, no previous report was found. However,
previous investigators reported contradictory results for
the relationship between nuclear beta-catenin in CRC
and clinicopathological characteristics. Zhang et al.
believed that nuclear beta-catenin accumulation is
related to tumor stage and/or metastasis [37]. However,
correlations between nuclear beta-catenin and important
clinicopathological variables were not observed in Bal-
dus’s study [38]. Our data demonstrated that nuclear
beta-catenin expression in metastatic SLN(s) is asso-
ciated with age, type of tumor, tumor cell differentiation,
tumor invasion depth, lymph node metastasis, liver
metastasis and TNM stage. This result indicates that
nuclear beta-catenin overexpression is related to an
advanced tumor stage and poor tumor cell differentia-
tion, which may be helpful for explaining the association
between nuclear beta-catenin overexpression in meta-
static SLN(s) and liver metastasis. As for age, contro-
versy remains about the differences in CRC between
younger and older patients. Some researchers indicated
no differences in relation to the major histopathological
features and the pathologic grade or stage in younger
CRC patients compared with older patients [39,40]. On
the other hand, some studies reported young CRC
patients were more likely to be characterized with poor
differentiation and higher grade, later stage (III/IV), and
poor prognosis [41,42]. Our results are mainly consis-
tent with the latter finding. In our research, patients
younger than 55 years had a higher incidence rate of
liver metastases, and nuclear beta-catenin overexpres-
sion in metastatic SLN(s) was more evident. Thus, these
data may also suggest the association between advanced
tumor and nuclear beta-catenin overexpression, and the
close association of beta-catenin overexpression in meta-
static SLN(s) and age with liver metastasis. The low sus-
picion for CRC and the low rate of screening
colonoscopy in younger patients, which may directly
cause delay in making the right diagnosis, may be the
main reasons for the different research results. In the
present study, we did not find significance between gen-
der and nuclear beta-catenin overexpression in meta-
static SLN(s) or liver metastasis.
Univariate analysis demonstrated that nuclear beta-
catenin overexpression in metastatic SLN(s) is associated
with liver metastasis, which coincides with the result of
immunohistochemical analysis. To obtain a more precise
estimate of the influence of nuclear beta-catenin overex-
pression in metastatic SLN(s) on liver metastasis, a mul-
tivariate logistic regression analysis model was
constructed to discriminate the independent risk factors
of synchronous liver metastasis. Nuclear beta-catenin
overexpression in metastatic SLN(s) remains in the
model (Table 4), suggesting that nuclear beta-catenin
overexpression in metastatic SLN(s) may influence liver
metastasis independently. The current TNM staging sys-
tem for CRC has been useful in predicting the outcome
after definitive resection, but its potential value to pre-
dict distant metastasis is limited. Attempts have been
made to predict tumor behavior better by identifying
novel biologic prognostic factors. Although previous stu-
dies have indicated that nuclear beta-catenin expression
was associated with liver metastasis, the proof was lim-
ited to the immunohistochemical analysis of primary
tumor. In the current study, nuclear beta-catenin over-
expression was found not only in the metastatic SLN(s),
but also in the matched metastatic liver lesions. More-
over, the association between nuclear beta-catenin over-
expression and liver metastasis was verified by clinical
data. Nuclear beta-catenin expression in metastatic SLN
(s) may become a possible clinically useful marker to
distinguish between highly metastatic CRC and less
aggressive CRC.
In this study, only the association of nuclear beta-cate-
nin overexpression in metastatic SLN(s) with synchro-
nous liver metastases was analyzed. To exclude the
influence of treatments on liver metastasis, liver metas-
tases that occurred after surgical treatments were not
examined. Investigating whether the factors associated
with synchronous metastasis also play an important role
in metastasis that occurs after surgery is also a very use-
ful direction to pursue. Intriguingly, 31 cases showed
nuclear beta-catenin overexpression in metastatic SLN
(s) in patients without synchronous liver metastases.
Examining if liver metastases would occur more fre-
quently in these cases than in those without
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under follow-up, and the same type patients are being
gathered. Further studies are necessary to evaluate the
relationship between nuclear beta-catenin overexpres-
sion in metastatic SLN(s) and liver metastases occurring
after surgery in CRC.
Conclusions
Our data demonstrated that nuclear beta-catenin over-
expression in metastatic SLN(s) is associated with syn-
chronous liver metastasis, while nuclear beta-catenin
expression in liver metastatic lesions is related to that in
metastatic SLN(s). Both clinical and pathological data
authenticate our conclusion. Nuclear beta-catenin over-
expression in metastatic SLN(s) in CRC may be used as
a valuable predictor of liver metastasis. Clinical surveys
with larger study cohorts will be needed to verify our
findings.
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